SureTrader SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > StocksDiva Bio Bin

SLTM. at/close. Solta Medical Reports First Quarter Results

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
PoemStone Member Profile
Followed By 881
Posts 27,820
Boards Moderated 1
Alias Born 11/05/10
160x600 placeholder
U.S. Stocks Set To Fall As Volatile Week Leaves Investors Wary
Top Equities Stories Of The Day
Majedie Asset Management Ltd Form 8.3 - Royal Dutch Shell Plc
e> TIDMRDSB FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: Majedie Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: ROYAL DUTCH SHELL PLC Use a separate form for each offeror/offeree (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest 27 August 2015 practicable date prior to the disclosure (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other NO party to the offer? If it is a cash offer or possible cash offer, state "N/A" 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: Class 'B' ord Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 25,795,667 1.06 (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 25,795,667 1.06 All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors' and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. 1. Purchases and sales Class of relevant Purchase/sale Number of securities Price per unit security Class 'B' ord Purchase 19,054 1628.62 Class 'B' ord Class 'B' ord (b) Cash-settled derivative transactions Class of Product description Nature of dealing Number of Price relevant e.g. CFD e.g. opening/closing a long/short position, increasing/reducing reference per security a long/short position securities unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of Product Writing, Number of Exercise Type Expiry Option relevant description purchasing, securities price e.g. American, European etc. date money security e.g. call selling, to which per paid/ option varying option unit received etc. relates per unit (ii) Exercise Class of Product description Exercising/ Number of Exercise relevant e.g. call option exercised securities price per security against unit (d) Other dealings (including subscribing for new securities) Class of relevant Nature of dealing Details Price per unit security e.g. subscription, conversion (if applicable) 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" None (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? NO Date of disclosure: 28 August 2015 Contact name: James Tanqueray Telephone number: 020 7618 3949 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel's website at This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Majedie Asset Management Ltd via Globenewswire HUG#1948229
Winners, Losers in China's Upheaval
Icahn Takes a Stake in Copper Giant Freeport-McMoRan
ADRs End Higher; Syngenta Declines
Google Rebuffs European Union on Antitrust Charges --Update
United Continental, Activision to Join S&P 500
Margin Calls Bite Investors, Banks
Merger Monday Rolls Ahead; Whiplash For Netflix Holders
PoemStone   Tuesday, 05/01/12 05:00:30 PM
Re: PoemStone post# 6284
Post # of 11517 
SLTM. at/close. Solta Medical Reports First Quarter Results
First Quarter Revenue Up 23% from Prior Year
Launch of Liposonix Exceeds Expectations

HAYWARD, Calif., May 1, 2012 /PRNewswire/ -- Solta Medical, Inc. (SLTM), a global leader in the medical aesthetics market, today announced results for the first quarter ended March 31, 2012. Revenue for the first quarter was $32.5 million, an increase of $6.0 million, or 23%, as compared to the first quarter of 2011. Revenue from Liposonix, the Company's non-invasive fat reduction system, was $7.6 million, which was generated from sales of 78 new systems, 11 system upgrades, and associated consumables. As previously announced, the Company launched the second generation Liposonix system in January 2012. In addition, product revenue from treatment tips and consumables grew sequentially from the fourth quarter of 2011 by 6% and accounted for 52% of total revenue.

"The acceptance and feedback from physicians and their patients on the second generation Liposonix fat reduction procedure continues to be very positive. In fact, 20 of the key physician opinion leaders with which we placed Liposonix systems for their evaluation and feedback in December have purchased the system," said Stephen J. Fanning, Chairman, President & CEO. "In the first quarter, much of our sales and marketing efforts were devoted to the launch of Liposonix, especially in North America and we achieved a stronger than expected start. Going forward we are enhancing our focus to promote sales growth across all our product lines while we build on the market momentum for Liposonix. In addition, we look forward to expanding our Liposonix commercialization efforts in markets outside of North America over the course of the year, pending additional regulatory clearances."

GAAP net loss for the quarter was $8.8 million as compared to GAAP net loss of $1.0 million reported for the first quarter of 2011. Non-GAAP net loss for the quarter was $0.8 million or $0.01 per share as compared to non-GAAP net income of $0.7 million, or $0.01 per diluted share for same period last year.

Solta Medical's GAAP results for the first quarter include a $4.7 million charge for a fair value reassessment of the expected earn out payments associated with the acquisition of Liposonix, $2.1 million of non-cash amortization and other acquisition related charges, and $1.1 milllion of non-cash stock based compensation charges. The Company provides non-GAAP financial measures that exclude these charges and expenses. A reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

Financial Outlook for 2012

The company updated its financial outlook for 2012 as follows:

Revenue for the full year 2012 is now expected to be in the range of $140 million to $143 million representing year-over-year revenue growth of 20% to 23% driven by sales of the second generation Liposonix system.
Non-GAAP gross margin is estimated to be in the range of 63% to 66% for the full year 2012. Non-GAAP gross margin excludes non-cash amortization charges, non-cash stock based compensation charges, severance costs, and acquisition related adjustments. Non-GAAP gross margin for the first quarter was approximately 68%.
Positive non-GAAP EBITDA for every quarter and for the full-year 2012. Non-GAAP EBITDA excludes non-cash amortization charges, non-cash stock based compensation charges, severance costs, and acquisition related adjustments. Positive non-GAAP EBITDA for the first quarter was $550,000.
Non-GAAP Presentation

To supplement the condensed consolidated financial information presented on a GAAP basis, management has provided non-GAAP gross margin, non-GAAP operating income (loss), non-GAAP EBITDA, non-GAAP net income (loss) and non-GAAP earnings (loss) per share measures that exclude the impact of acquisition related adjustments, severance costs, acquisition related costs, and stock-based compensation expenses. The Company believes that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of the Company's ongoing operating results and trends, compared with historical results. This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures attached to this release.

Conference Call Information

The Company will also host a conference call and webcast today, Tuesday, May 1, 2012, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the financial results and current corporate developments. The dial-in number for the conference call is 877-941-6010 for domestic participants and 480-629-9770 for international participants.

To access the live webcast of the call, go to Solta Medical's website at and click on Investor Relations. An archived webcast will also be available at

About Solta Medical, Inc.

Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers six aesthetic energy devices to address a range of issues, including skin resurfacing and rejuvenation with Fraxel® and Clear + Brilliant(TM), body contouring and skin tightening with Liposonix® and Thermage® and acne reduction with Isolaz® and CLARO(TM). As the innovator and leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Using similar fractional laser technology, Clear + Brilliant is a unique, cost-effective treatment to prevent and improve the early signs of photoaging. For body contouring, Liposonix is a non-surgical treatment to reduce waist circumference with advanced high-intensity focused ultrasound (HIFU) technology to permanently destroy targeted fat beneath the skin. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. Isolaz was the first laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the first FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. More than two million procedures have been performed with Solta Medical's portfolio of products around the world. For more information about Solta Medical, call 1-877-782-2286 or log on to

Forward-Looking Statements

5-bagger Contest on "Dawgg".
DD Picks on
HOSS TRACKZ. Low Floats. Charts. And Picks.
Dogs of the Dow.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist